Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.34 |
| ▸ | FABP7 | O15540 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7764 | 0.84 | CA1 (0.53) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL28101345 | 0.84 | CA1 (0.44) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL27768296 | 0.83 | CA1 (0.41) | CA1CA2HTR2AKMT2AFABP5 | |
| Dimethylformamide SCHEMBL28310394 | 0.82 | CA1 (0.43) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL28126451 | 0.79 | CA1 (0.40) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL28310443 | 0.75 | CA1 (0.44) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL22320252 | 0.73 | HTR2A (0.40) | CA1CA2HTR2AFABP5 | |
| Hydrochloric Acid SCHEMBL28129901 | 0.73 | KMT2A (0.38) | CA1CA2KMT2AFABP5FABP7 | |
| SCHEMBL18055683 | 0.72 | CA1 (0.42) | CA1CA2HTR2AKMT2AFABP5 | |
| SCHEMBL28202099 | 0.72 | CA1 (0.44) | CA1CA2HTR2AKMT2AFABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812439-B2 | KINASE INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-12-06 | — | — | EP | disclosed |
| EP-2145877-B1 | Aurora Kinase inhibitors | TAKEDA PHARMACEUTICAL (JP) | 2012-10-03 | — | — | EP | disclosed |
| EP-1812439-B1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2010-09-01 | — | — | EP | disclosed |
| EP-2145878-A2 | Aurora Kinase inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2010-01-20 | — | — | EP | disclosed |
| EP-2145877-A2 | Aurora Kinase inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2010-01-20 | — | — | EP | disclosed |
| WO-2009129401-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | WO | disclosed |
| EP-2081930-A2 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| EP-2079696-A2 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2009-07-22 | — | — | EP | disclosed |
| EP-1999135-A2 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2008-12-10 | — | — | EP | disclosed |
| EP-1931669-A1 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2008-06-18 | — | — | EP | disclosed |
| EP-1763524-A1 | INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2007-03-21 | — | — | EP | disclosed |
| EP-1694686-A1 | KINASE INHIBITORS | Takeda San Diego, Inc. (US) | 2006-08-30 | — | — | EP | disclosed |
| WO-2006066109-A2 | HYDROXYSTEROID DEHYDROGENASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006044687-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| WO-2006044753-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-04-27 | — | — | WO | disclosed |
| WO-2006023931-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20060041137-A1 | Kinase inhibitors | TAKEDA SAN DIEGO, INC. | 2006-02-23 | — | — | US | disclosed |
| WO-2005123672-A2 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005105788-A1 | INDOLE DERIVATIVES AND USE THEREOF AS KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2005-11-10 | — | — | WO | disclosed |
| WO-2005061519-A1 | KINASE INHIBITORS | TAKEDA SAN DIEGO, INC. (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041137-A1 | Kinase inhibitors | MAP3K19, MAP3K20, MAP3K1 | CA1 4656/4885CA2 3145/4885TDP1 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.